The National Institute for Health and Care Excellence (NICE) issued two final guidelines, recommending Pfizer’s Inlyta (axitinib) in kidney cancer, but rejecting Dendreon’s Provenge (sipuleucel-T) in prostate cancer.
In guidance issued to the NHS, the drug pricing watchdog recommended Inlyta as a second-line option for treating adults with advanced renal cell carcinoma (RCC). Patients should have failed treatment with a first-line tyrosine kinase inhibitor or a cytokine. The drug is only recommended for use in this patient population if Pfizer provides Inlyta with the discount agreed in the patient access scheme.
“NICE has previously recommended two drugs for advanced renal cell carcinoma, sunitinib and pazopanib both as first-line treatments and we are pleased to confirm that axitinib will be made available through the NHS for patients after these first-line treatments have failed. Based on the evidence available and the discount on the cost of the drug offered by Pfizer, the committee concluded that axitinib would offer good value for NHS money,” said Professor Carole Longson, Health Technology Evaluation Centre Director.
In its subsequent guidance, NICE rejected Dendreon’s Provenge for treating adults who have asymptomatic or minimally symptomatic metastatic non-visceral hormone-relapsed prostate cancer for which chemotherapy is not yet clinically indicated. NICE said that it will not be funded on the NHS because available evidence shows the price for the drug is too high for the benefit it may provide.
“Unfortunately Dendreon has been unable to show that sipuleucel-T works better than other treatments currently available. It was also not proven to delay the progression of the disease, unlike current treatments. Based on the evidence presented, NICE is unable to recommend the NHS provides funding for this drug, as it costs too much for the extra benefit it may provide,” Longson said.
Source: National Institute for Health and Care Excellence